CORS Publications – University of Copenhagen

Forward this page to a friend Resize Print Bookmark and Share

Department of Pharmacy > Research > CORS > Publications

CORS Publications

List of scientific publications by CORS affiliated authors

Sorted by publication date, most recent.

Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study.
Anna But, Marie L. De Bruin, Marloes T. Bazelier, Vidar Hjellvik, Morten Andersen, Anssi Auvinen, Jakob Starup-Linde, Marjanka K. Schmidt, Kari Furu, Frank de Vries, Øystein Karlstad, Nils Ekström, Jari Haukka.
Diabetologia. 2017 June 01.
doi:10.1007/s00125-017-4312-5

Evaluating the effectiveness of risk minimisation measures: the application of a conceptual framework to Danish real-world dabigatran data.
Nyeland ME, Laursen MV, Callréus T.
Pharmacoepidemiol Drug Saf. 2017 Apr 11.
doi: 10.1002/pds.4203

Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
Bouvy JC, Blake K, Slattery J, De Bruin ML, Arlett P, Kurz X.
Pharmacoepidemiol Drug Saf. 2017 Mar 26. 
doi:10.1002/pds.4196. [Epub ahead of print]

Trends in breast cancer incidence among women with type-2 diabetes in British general practice.
Bronsveld HK, Peeters PJ, de Groot MC, de Boer A, Schmidt MK, De Bruin ML.
Prim Care Diabetes. 2017 Feb 22. pii: S1751-9918(17)30024-4.
doi: 10.1016/j.pcd.2017.02.001. [Epub ahead of print] 

Lessons learned on the design and the conduct of Post-Authorization Safety Studies: review of 3 years of PRAC oversight.
Engel P, Almas MF, De Bruin ML, Starzyk K, Blackburn S, Dreyer NA.
Br J Clin Pharmacol. 2017 Apr;83(4):884-893.
doi: 10.1111/bcp.13165. 

Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance.
Aagaard L, Hallgreen CE, Hansen EH.
Int J Obes (Lond). 2016 Nov;40(11):1742-1747.
doi: 10.1038/ijo.2016.135. 

A Paradigm Shift Towards Patient Involvement in Medicines Development and Regulatory Science: Workshop Proceedings and Commentary.
Borup G, Bach KF, Schmiegelow M, Wallach-Kildemoes H, Bjerrum OJ, Westergaard N.
Ther Innov Regul Sci. 2016 May;50(3):304-311. 
doi: 10.1177/2168479015622668  

Recommendations for benefit-risk assessment methodologies and visual representations.
Hughes D, Waddingham E, Mt-Isa S, Goginsky A, Chan E, Downey GF, Hallgreen CE, Hockley KS, Juhaeri J, Lieftucht A, Metcalf MA, Noel RA, Phillips LD, Ashby D, Micaleff A; PROTECT Benefit-Risk Group.
Pharmacoepidemiol Drug Saf. 2016 Mar;25(3):251-62.
doi: 10.1002/pds.3958. 

Innovation of Medical Products: The Evolution of Regulatory Science, Research, and Education.
Spindler P, Bach KF, Schmiegelow M, Bedlington N, Eichler HG.
Ther Innov Regul Sci. 2016 Jan; 50(1):44-48.
doi: 10.1177/2168479015599810